{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:24:54Z","timestamp":1794900294205,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Polycystic ovarian syndrome (PCOS) is a common endocrinopathy with many clinical manifestations. The effects on women\u2019s lives start at puberty and can last throughout her lifetime. Women frequently experience anovulatory menstrual cycles, infertility, hirsutism, obesity and increased risk of diabetes mellitus, hypertension, lipid abnormalities, and metabolic syndrome. PCOS is a heterogenous disorder, and a diagnosis of exclusion. In general, women afflicted will have menstrual irregularities, ultrasound findings of abnormal ovarian size and morphology, and clinical or laboratory evidence of hyperandrogenism. This chapter reviews the current understanding of PCOS, associated metabolic abnormalities, and diagnosis in reproductive-aged women, as well as adolescents.<\/jats:p>","DOI":"10.1097\/grf.0000000000000563","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:04:05Z","timestamp":1595466245000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":61,"title":["Clinical Presentation and Diagnosis of Polycystic Ovarian Syndrome"],"prefix":"10.1097","volume":"64","author":[{"given":"JESSICA A.","family":"LENTSCHER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALAN H.","family":"DECHERNEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9378(15)30642-6","article-title":"Amenorrhea associated with bilateral polycystic ovaries","volume":"29","author":"Stein","year":"1935","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"132","author":"Azziz","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40200-018-0371-5","article-title":"Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach","volume":"17","author":"Toosy","year":"2018","journal-title":"J Diabetes Metab Disord"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2016.05.003","article-title":"Androgen excess: investigations and management","volume":"37","author":"Lizneva","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.13245","article-title":"PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude","volume":"86","author":"Kyritsi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1210\/jc.2005-2153","article-title":"Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1210\/jc.2005-2501","article-title":"Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria","volume":"91","author":"Franks","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2005-1457","article-title":"Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism","volume":"91","author":"Carmina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/er.2015-1018","article-title":"Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome","volume":"36","author":"Dumesic","year":"2015","journal-title":"Endocr Rev"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1017\/S0954422416000287","article-title":"Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges","volume":"30","author":"Jeanes","year":"2017","journal-title":"Nutr Res Rev"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40618-016-0523-8","article-title":"New markers of insulin resistance in polycystic ovary syndrome","volume":"40","author":"Polak","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1007\/s13277-013-1595-0","article-title":"Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/NSS.S127475","article-title":"Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies","volume":"10","author":"Fernandez","year":"2018","journal-title":"Nat Sci Sleep"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1210\/jc.2014-3911","article-title":"Subchronic sleep restriction causes tissue-specific insulin resistance","volume":"100","author":"Rao","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.AOG.0000167408.30893.6b","article-title":"Screening women with polycystic ovary syndrome for metabolic syndrome","volume":"106","author":"Dokras","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/humupd\/dmp008","article-title":"Metabolic features of the reproductive phenotypes of polycystic ovary syndrome","volume":"15","author":"Moran","year":"2009","journal-title":"Hum Reprod Update"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-018-0680-5","article-title":"Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome","volume":"17","author":"Glintborg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1017\/S0033291718002076","article-title":"Depression, anxiety and perceived stress in women with and without PCOS: a community-based study","volume":"49","author":"Damone","year":"2019","journal-title":"Psychol Med"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.fertnstert.2008.09.018","article-title":"Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"92","author":"Moran","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:18:11Z","timestamp":1747048691000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000563","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}